SAM
MRTX

Stenahm Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Stenahm Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,300
Closed -$3.41M – 25
2021
Q3 		$3.41M Hold
19,300
– – 2.23% 19
2021
Q2 		$3.12M Buy
+19,300
New +$3.1M 1.91% 20

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Stenahm Asset Management's MRTX Position: Q4 2021 in Review

Stenahm Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 19,300 shares — an estimated $3.41M sold.

Stenahm Asset Management first reported a position in MRTX in Q2 2021 and held it in 2 quarters. The position peaked at $3.41M in Q3 2021. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

  • Stenahm Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Stenahm Asset Management sold 19,300 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $3.41M.
  • Stenahm Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Stenahm Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $3.41M in Q3 2021.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Stenahm Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.